Recce https://validator.w3.org/feed/docs/rss2.html Biocurious: US military enlists Aussie biotechs in the germ warfare battle Recce lands Brazil patent as global anti-infectives footprint expands Break it Down: Recce in pole position for mega tax rebate Company Announcements Intellectual Property Burn Wound Infections The world is running out of antibiotics. New research could make old ones work again Pre-clinical Indications Diabetic Foot Infections R327 shows strong efficacy in lung infection trial US Army backs Recce’s synthetic antibiotic for burns Break it Down: Recce expands US Army research deals to fight deadly pathogens Executive Edge: James Graham on Recce’s fight against superbugs Recce expands US government collaborations WHO 2025 Antibacterial Pipeline Report 2025 Wrapped: Recce Pharmaceuticals wraps up a healthy past 12 months UTI Recce secures $30m debt facility to support Phase III trials Board of Directors and Management Team Product Candidates Overview Manufacturing Corporate Governance Recce Pharmaceuticals Targets Diabetic Foot Infections With First-in-Class Synthetic Anti-Infective Recce to expand Phase II trial for diabetic foot infections Events and Presentations Case Studies Recce Pharmaceuticals doses all patients in phase II skin infection trial Recce’s RECCE® 327 Topical Gel targets superbugs, speeds wound healing RECCE® 327 Topical Gel shows strong preclinical results Share Price and Tools Contact us Recce raising up to $15.8m for Phase III trials Australian biotech points to potential superbug use as gel treats skin infections in phase 2 trial Biocurious: For Recce, our near neighbour was the obvious place to launch a diabetes-related trial Break it Down: Recce partners with the US Army Acute Bacterial Skin and Skin-Structure Infections Mechanism of Action Pipeline Testing events FAQ Synthetic Gel Shows Utility Across ABSSSI, Company Sees Other Indications Recce soars on phase II skin infection trial results Complete patent protection for 2 Recce anti-infective treatments About us Recce Pharmaceuticals doses all patients in Phase 2 clinical trial of RECCE® 327 topical gel for skin infections Sepsis Recce gets Indonesian nod for phase III trial of diabetic foot infection treatment Recce green lit to begin dosing in registrational Phase 3 trial for diabetic foot infections From No More Tears to no more superbug fears Home